PT - JOURNAL ARTICLE AU - Shao, Dan AU - wang, shuxia TI - Value of pretreatment <sup>18</sup>F-FDG PET/CT in predicting progression-free survival of patients with nonmycosis fungoides/Sézary syndrome primary cutaneous lymphomas DP - 2019 May 01 TA - Journal of Nuclear Medicine PG - 1248--1248 VI - 60 IP - supplement 1 4099 - http://jnm.snmjournals.org/content/60/supplement_1/1248.short 4100 - http://jnm.snmjournals.org/content/60/supplement_1/1248.full SO - J Nucl Med2019 May 01; 60 AB - 1248Objectives: To analyze the value of pretreatment PET/CT for predicting disease progression or death in non-MF/SS CML patients. Methods: The following clinical information was collected and analyzed for all patients: pretreatment maximum standardized uptake value (SUVmax); age; lymphoma type; skin lesion location, morphology, and range; treatment method; presence of B symptoms; mammary lactic dehydrogenase level; β-microglobulin level; Eastern Cooperative Oncology Group performance status (ECOG PS) score; international prognostic index score; lymph node infiltration; bone infiltration; extranodal lesion location; and survival time. The correlation between relevant prognostic factors and progression-free survival (PFS) was analyzed using the Cox regression model. Results: The Kaplan-Meier analysis results showed that the PFS for 30 patients was 24.592±4.507 months (95% confidence interval [CI]: 15.759, 33.425). The Cox regression model showed that the PFS of SUVmax-negative patients was longer than that of SUVmax-positive patients (p=0.028 and Exp [B]=6.188). The Cox analysis results showed that pretreatment SUVmax, skin lesion range, skin lesion location, treatment method, presence of B symptoms, ECOG score, and lymph node infiltration were prognosis-related factors. Conclusions: Pretreatment PET/CT had a strong prognostic value in predicting the disease progression and death of non-MF/SS CML patients. In addition, the PFS of pretreatment SUVmax-positive patients was shorter than that of SUVmax-negative patients.